NewLimit, a startup that goals to extend how lengthy individuals can reside a wholesome life by genetically programming their cells, has raised a $130 million Collection B led by Kleiner Perkins.
New traders Nat Friedman, Daniel Gross, and Khosla Ventures additionally invested, as did returning backers Founders Fund, Dimension Capital, Elad Gil, Garry Tan, Patrick Collison and others. The fundraise comes two years after the corporate raised a $40 million Collection A.
Based over 4 years in the past by Coinbase CEO Brian Armstrong (pictured above), former GV accomplice Blake Bryers, and stem cell professor Jacob Kimmel, NewLimit claims it has made vital progress in the direction of growing remedies that may restore youthful traits to aged cells.
Bryers advised TechCrunch the corporate has found three prototype medicines that reprogram liver cells. NewLimit’s lab experiments, he mentioned, exhibit this rejuvenation can restore the cells’ means to course of fats and alcohol.
The corporate measures its progress by contrasting how cells from a youthful particular person and an older individual reply to the substances. An older liver cell that has gone via NewLeaf’s epigenetic reprogramming behaves extra like a youthful cell, Bryers mentioned.
Promising early outcomes however, NewLimit continues to be a number of years away from beginning human trials.
Within the meantime, the corporate desires to proceed growing new anti-ageing medication utilizing an AI mannequin after which testing probably the most promising of those machine-generated medication in its laboratory. “What the AI mannequin permits us to do is run all these experiments in simulation after which solely comply with up on probably the most promising subset,” Bryers mentioned, including that the info factors from the experiment are then used to retrain the AI mannequin in a course of often known as “lab in a loop.”
Techcrunch occasion
Berkeley, CA
|
June 5
BOOK NOW
Different noteworthy biotech startups growing medication that goal to extend lifespan embrace Retro Biosciences, which raised $180 million from OpenAI CEO Sam Altman two years in the past and is reportedly elevating a $1 billion Collection A; and Altos Labs, which launched with $3 billion in 2022, and is backed by Jeff Bezos.